CAR T-cell Therapy
CAR-T Cell Therapy for Lymphoma
This trial tests a new treatment using lab-modified immune cells to target and kill cancer cells in patients with certain types of lymphoma that haven't responded to other treatments. The modified cells are designed to better locate and destroy cancer cells. This new approach extends the capacity of the patient's own immune cells to detect and eliminate cancer cells.
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor
JNJ-64619178 for Cancer
This trial is testing a new cancer drug to see what doses are tolerated by patients with different types of cancer, including lymphoma and solid tumors. The goal is to also find out what doses of the drug might be effective in treating these cancers.
Radioactive Agent
Iobenguane (131-I) + Vorinostat for Neuroblastoma
This trial tests a combination of a radioactive drug and a cancer-fighting pill in patients with a specific type of neuroblastoma that hasn't responded well to other treatments. The radioactive drug kills cancer cells, and the pill makes them more vulnerable to the drug.
JAK Inhibitor
MMB for Myelofibrosis
This trial aims to provide ongoing access to momelotinib for patients with certain types of myelofibrosis who are already taking the drug and have not seen their disease get worse. The study will also look at how long these patients live without developing leukemia. Momelotinib has been studied for myelofibrosis and other related conditions.
Popular Filters
Trials for Tumors Patients
Behavioral Intervention
Exercise Program for Cancer
This trial is testing the ACE Program, a structured exercise plan for adult cancer survivors. The program aims to improve their physical well-being and quality of life through consistent, personalized exercise. It may also help prevent new cancers from developing.
Monoclonal Antibodies
TSR-022 for Cancer
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Trials for Metastatic Patients
Monoclonal Antibodies
TSR-022 for Cancer
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Monoclonal Antibodies
MK-4830 + Pembrolizumab for Cancer
This trial is testing a new drug called MK-4830 alone and with other cancer treatments to see if it is safe and effective. It focuses on cancer patients, including those in China. The treatments work by helping the immune system fight cancer and killing cancer cells.
MDM2 Inhibitor
BI 907828 for Advanced Cancer
This trial is testing a new cancer drug, BI 907828, to see if it's effective and safe. Participants will take BI 907828 either once every three weeks or twice every four weeks, depending on how well they tolerate the drug. The goal is to see if BI 907828 causes tumors to shrink.
Trials for EGFR Positive Patients
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Immunotherapy
MK-0482 + Pembrolizumab for Advanced Cancer
This trial tests a new drug, MK-0482, alone and with pembrolizumab, in patients with advanced cancers who have no other treatment options. MK-0482's safety and effectiveness are being evaluated, while pembrolizumab helps the immune system fight cancer. Pembrolizumab has been widely studied and used in various cancers, showing effectiveness and safety in combination with other treatments.
Chemotherapy
EMB-01 for Advanced Cancer
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
Small Molecule Inhibitor
BLU-451 for Lung Cancer
This trial is testing a new drug called BLU-451, alone and with chemotherapy, in patients with advanced cancers that have specific EGFR mutations. The drug works by blocking signals that make cancer cells grow.
Chemotherapy
EMB-01 for Gastrointestinal Cancer
This trial is testing a new drug called EMB-01 for patients with advanced digestive system cancers who haven't responded to other treatments. The drug works by targeting specific genetic changes in the cancer cells to stop their growth.
Phase 3 Trials
Kinase Inhibitor
Encorafenib + Cetuximab for Colorectal Cancer
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Trials With No Placebo
Behavioral Intervention
Exercise Program for Cancer
This trial is testing the ACE Program, a structured exercise plan for adult cancer survivors. The program aims to improve their physical well-being and quality of life through consistent, personalized exercise. It may also help prevent new cancers from developing.
Monoclonal Antibodies
TSR-022 for Cancer
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
View More Related Trials
Frequently Asked Questions
Introduction to oncology
What are the top hospitals conducting oncology research?
When it comes to groundbreaking clinical trials in the field of oncology, several hospitals have made significant contributions. In New york City, Memorial Sloan Kettering Cancer Center takes the lead with an impressive 10 ongoing trials and a remarkable history of 260 completed studies since their first recorded trial in 1977. This prestigious institution has been at the forefront of cancer research for decades, constantly striving to find innovative treatments and improve patient outcomes.
Down in Houston, Texas, The University of Texas MD Anderson Cancer Center is making waves as well. With nine active oncology trials and a portfolio that boasts 88 completed studies since their inaugural trial in 2006, this renowned center is dedicated to pushing the boundaries of cancer research and providing cutting-edge care to patients from around the world.
In Dallas, GSK Investigational Site has emerged as an important player in the field with eight active oncology trials currently underway. Since recording their first trial in 2008, they have conducted a total of 16 studies thus far. The dedication shown by this site highlights its commitment to advancing our understanding and treatment options for various types of cancers.
Heading back up north to Boston's Massachusetts General Hospital (MGH), medical professionals are engaged in eight active oncology trials while having achieved an impressive tally of176 previous investigations since conducting its initial trial backin1999.MGH's contribution towards pioneering new treatments underscores its commitment towards better outcomes for patients battling cancer.
Lastly,GSK Investigational Site based outof Toronto also deserves recognition for its efforts withinthe realmofoncologicalclinicaltrials.Thiscenteriscurrentlyengagedineightactiveandongoingtreatmentsforvariousformsoccancers.Sincemakingitsmarkin2014,thisinvestigationalrehasconducted25studiesfocusedonimprovingpatientcareandtacklingtheproblemsofwinningthesefightsagainstthedisease.
These esteemed institutions stand as beacons of hope and progress in the fight against cancer. Through their tireless efforts, researchers and clinicians are constantly striving to find new ways to prevent, diagnose, and treat this devastating disease. Each trial conducted brings us closer to more effective therapies and improved outcomes for patients worldwide.
Which are the best cities for oncology clinical trials?
When it comes to oncology clinical trials, several cities have emerged as hotspots for cutting-edge research. New york City leads the way with 50 active trials investigating a diverse range of treatments such as Arm 3: JAKi Naïve Combination Arm, Gene-modified (GM) T cell therapy, and BLU-451. Houston, Texas closely follows with 49 ongoing studies focused on interventions like SAR443216-Dose Expansion for metastatic gastric cancers with HER2 low expression and CC-90011. Additionally, Boston, Massachusetts offers 33 active trials exploring therapies such as P-PSMA-101 CAR-T cells and GM T cell therapy. These cities showcase a dedication to advancing oncology care through rigorous clinical trials that pave the way for improved treatment options for cancer patients.
Which are the top treatments for oncology being explored in clinical trials?
Exciting advances in oncology research are taking place through various clinical trials, focusing on the exploration of top treatments. Gemcitabine stands out with 81 all-time oncology trials and continues to be investigated in two active studies since its introduction in 2001. Joining the ranks is EMB-01, a newer contender introduced in 2018, currently being tested in two active oncology trials alongside BI 907828, both showing promise for future treatment options. Another intriguing development is ATLCAR.CD30 cells—an innovative therapy first listed in 2016—with ongoing investigation occurring through two active oncology trials. These cutting-edge approaches offer hope for improving outcomes and transforming cancer care.
What are the most recent clinical trials for oncology?
Exciting advancements are taking place in the field of oncology, with recent clinical trials offering new possibilities for patients. One notable trial is exploring a Part B Expansion, which aims to expand on previous findings and assess safety and efficacy in a larger cohort. Additionally, Arm 1 is investigating an innovative approach to treatment in Phase 2, providing hope for improved outcomes. Another study focuses on the potential benefits of combining triplet therapies for certain types of cancer, aiming to enhance overall response rates. Furthermore, MDK-703 shows promise when utilized alongside checkpoint inhibitors in both Phase 1 and Phase 2 trials. Lastly but not leastly VIP236's dose escalation trial seeks to determine optimal dosage levels for effective treatment options down the line.. These ongoing trials offer immense potential and bring us closer towards more effective strategies against cancer.
What oncology clinical trials were recently completed?
Numerous oncology clinical trials have recently concluded, showcasing the progress being made in cancer research. In April 2022, OncoNano Medicine's pegsitacianine trial and Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA trial achieved their completion milestones. Earlier this year, Adagene Inc.'s ADG116 trial was finalized in February 2022. Other significant completed trials include HiberCell's Pembrolizumab study (November 2021), AstraZeneca's Capivasertib study (October 2021), and Mirati Therapeutics' MRTX849 study (August 2021). These examples highlight the commitment of researchers to advancing treatments for various types of cancers and offer hope to patients worldwide.